versameb Revenue and Competitors
Estimated Revenue & Valuation
- versameb's estimated annual revenue is currently $3.3M per year.
- versameb's estimated revenue per employee is $155,000
Employee Data
- versameb has 21 Employees.
- versameb grew their employee count by 5% last year.
versameb's People
| Name | Title | Email/Phone |
|---|
versameb Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is versameb?
Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business team. The company's focus is the development of novel RNA-based therapeutics. Versameb's proprietary VERSagile technology platform enables efficient development of functional mRNA molecules in multiple disease areas with high unmet medical need including dermatology, oncology and myology.
keywords:N/A
N/A
Total Funding
21
Number of Employees
$3.3M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
versameb News
5 April 2022, Basel, Switzerland: Versameb AG (Versameb), focused on discovering and developing innovative RNA-based drugs,...
Enables Versameb to use Touchlight's proprietary doggybone DNA vector technology to support the development of novel mRNA-based therapeutics...
UK headquartered Touchlight has agreed a development and manufacturing pipeline agreement with Swiss company, Versameb.
Other Companies in Basel
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4M | 21 | 17% | N/A |
#2 | $3.4M | 22 | N/A | N/A |
#3 | $2.2M | 22 | -31% | N/A |
#4 | N/A | 24 | 26% | N/A |
#5 | N/A | 27 | 35% | N/A |